Subscribe to The Podcast by KevinMD. Catch up on old episodes! Join us with guest Kimberly Jackson-Bekemeier, a family physician with a personal story of managing Type 1 diabetes amidst the pandemic. Kimberly shares her journey of struggling with the d…
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
Despite advancements in health information technology (HIT), the prevalence of diabetes in the United States continues to be high and is the seventh leading cause of death. Diabetes management in underserved communities has challenges concerning health…
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
Eli Lilly’s news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
Subscribe to The Podcast by KevinMD. Catch up on old episodes! Our guest today is James Malone, an endocrinologist and health care executive with over 30 years of experience in the field of diabetes. James has seen firsthand the challenges that many pe…
Twitter has been a hotbed for the burgeoning insulin access movement and activism surrounding other medical conditions. For people with diabetes, the platform has helped propel concern about insulin prices into policy. Can it continue to win with hashtags?
On January 2020, I got the dreaded call: You have Type 1 diabetes. The rest is a blur. I went into a global pandemic, one of the highest risk categories, a red lab value that stared at me “HgbA1c > 15.” As a family physician, I was sup…
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
